Sintx Technologies, Inc. (NASDAQ:SINT) Sees Large Drop in Short Interest

31 Dec 2025, 23:01 by Danessa Lincoln · The Markets Daily

Sintx Technologies, Inc. (NASDAQ:SINT – Get Free Report) was the recipient of a significant drop in short interest in December. As of December 15th, there was short interest totaling 171,790 shares, a drop of 23.0% from the November 30th total of 223,234 shares. Based on an average daily volume of 117,075 shares, the days-to-cover ratio is presently 1.5 days. Currently, 4.9% of the shares of the stock are sold short. Currently, 4.9% of the shares of the stock are sold short. Based on an average daily volume of 117,075 shares, the days-to-cover ratio is presently 1.5 days.

Sintx Technologies Stock Performance

NASDAQ SINT traded up $0.10 during trading hours on Wednesday, reaching $3.86. The stock had a trading volume of 89,407 shares, compared to its average volume of 614,403. Sintx Technologies has a 52-week low of $1.71 and a 52-week high of $7.36. The stock has a fifty day moving average of $3.57 and a 200 day moving average of $3.58. The stock has a market cap of $14.22 million, a P/E ratio of -0.68 and a beta of 0.63.

Sintx Technologies (NASDAQ:SINT – Get Free Report) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($3.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($2.91). The business had revenue of $0.21 million for the quarter, compared to analysts’ expectations of $0.20 million. Sintx Technologies had a negative return on equity of 218.25% and a negative net margin of 775.12%.

Insiders Place Their Bets

In other news, CIO Gregg R. Honigblum acquired 8,200 shares of the business’s stock in a transaction on Monday, December 8th. The shares were acquired at an average price of $4.26 per share, for a total transaction of $34,932.00. Following the completion of the transaction, the executive directly owned 201,067 shares of the company’s stock, valued at approximately $856,545.42. The trade was a 4.25% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have acquired a total of 89,000 shares of company stock valued at $342,002 in the last quarter. Insiders own 4.08% of the company’s stock.

Institutional Investors Weigh In On Sintx Technologies

Several hedge funds have recently added to or reduced their stakes in the business. Virtus Wealth Solutions LLC acquired a new stake in Sintx Technologies during the 3rd quarter worth about $388,000. Veracity Capital LLC purchased a new stake in shares of Sintx Technologies in the second quarter worth about $233,000. Finally, Geode Capital Management LLC grew its holdings in Sintx Technologies by 33.5% during the second quarter. Geode Capital Management LLC now owns 15,339 shares of the company’s stock worth $49,000 after acquiring an additional 3,848 shares during the period. 18.38% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on SINT shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Sintx Technologies in a research report on Wednesday, October 8th. Wall Street Zen downgraded Sintx Technologies from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. Finally, Ascendiant Capital Markets decreased their price target on shares of Sintx Technologies from $25.00 to $16.00 and set a “buy” rating for the company in a report on Monday, December 8th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $16.00.

View Our Latest Analysis on Sintx Technologies

About Sintx Technologies

(Get Free Report)

Sintx Technologies, Inc (NASDAQ: SINT) is a medical materials company specializing in the development and manufacture of silicon nitride-based biomaterials for surgical and implantable medical devices. Its proprietary silicon nitride ceramic combines mechanical strength, biocompatibility and intrinsic antimicrobial properties, positioning it as an alternative to traditional metal and polymer implant materials. Sintx’s primary focus is on applications in spinal fusion, trauma fixation and dental implantology, where device performance and long-term biological response are critical.